MALT1i is highly synergistic with PI3K inhibition in ABC-DLBCL. (A) Dose response for individual drugs against signaling hubs in the BCR, PI3K, and TLR pathways in 4 ABC-DLBCL lines. Gray shaded area represents on-target dose. (B) Heat map of CIs at fraction affected 50% (Fa50) for the indicated drugs in combination with C3 or MI-2 in 4 ABC-DLBCL cell lines. For white boxes, CI50 (combination index) was not calculated because GI50 (growth inhibition) was not reached.